Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcers
Phase 2
Active, not recruiting
- Conditions
- Diabetic Foot Ulcers
- Interventions
- Drug: Antimicrobial Peptide PL-5 Topical Spray and Placebo
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2025-05-25
- Target Recruit Count
- 90
- Registration Number
- NCT06189638
- Locations
- 🇺🇸
ILD Research Center, Vista, California, United States
🇺🇸Bioresearch Partner Holdings, LLLP, Miami, Florida, United States
🇺🇸Santos Research Center, Corp, Tampa, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath